Clinical Trials Logo

Filter by:
NCT ID: NCT05943197 Recruiting - Oral Microbiota Clinical Trials

Clinical and Microbiological Approach in Orthopedic Treatment of Patients When Choosing a Structural Material

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Today, there is a wide range of structural materials on the market, different in chemical, physical and biological properties, and information about them is very often limited only by the manufacturer's instructions, which allows to determine, at best, only the scope. In this regard, there are difficulties in choosing the optimal material for this particular situation, since without a thorough approach to studying the properties of the main materials used in dentistry, it seems difficult to provide high-quality dental care, the result of which is functional usefulness, aesthetics and durability.The problem of an individual approach to the choice of structural material from the standpoint of personalized medicine is even less studied - there are no data in the literature on the role of normal and pathogenic microflora in the development of destructive changes in structures and the development of complications, taking into account a personalized approach when analyzing the composition of the microbiota of the oral cavity, biochemical parameters of the oral fluid, blood depending on the material from which the structure is made.

NCT ID: NCT05941897 Active, not recruiting - Clinical trials for Advanced or Metastatic NSCLC

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

LOTOS
Start date: June 21, 2023
Phase: Phase 2
Study type: Interventional

A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

NCT ID: NCT05940974 Active, not recruiting - Clinical trials for Shoulder Arthropathy

Quality of Life, Functional Outcomes and Costs in Shoulder Arthroplasty

Start date: July 11, 2023
Phase:
Study type: Observational

This prospective observational study aims to collect and analyse data on functional outcomes, quality of life indicators, and costs in patients undergoing primary total shoulder arthroplasty (shoulder replacement) surgery.

NCT ID: NCT05940909 Recruiting - Bioequivalence Clinical Trials

Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions

Start date: June 24, 2023
Phase: Phase 1
Study type: Interventional

This is an open-labeled, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Triplixam®, 10 mg/2.5 mg/10 mg tablets) or the test (Perindopril Erbumine/ 8 mg/2.5 mg/10 mg Tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent.

NCT ID: NCT05940298 Recruiting - Breast Cancer Clinical Trials

Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8

Start date: July 3, 2023
Phase: Phase 1
Study type: Interventional

The study should evaluate the biological distribution of 99mTc-DB8 in patients with prostate cancer and breast cancer. The primary objective are: 1. To assess the distribution of [99mTc]Tc- DB8 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of [99mTc]Tc- DB8. 3. To study the safety and tolerability of the drug [99mTc]Tc- DB8 after a single injection in a diagnostic dosage. The secondary objective are: 1. To compare the obtained [99mTc]Tc- DB8 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients.

NCT ID: NCT05939687 Recruiting - Surgery Clinical Trials

Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection

ProMeLAR
Start date: June 5, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare the efficacy of using polypropylene mesh for hernia prevention after stoma closure in patients with colorectal cancer and non-mesh repair. The main question it aims to answer is: can mesh help prevent hernia? Participants will be divided into 2 groups: with and without mesh using. They must be followed up for 2 years after enrollment in the study. Researchers will compare mesh and non-mesh groups to evaluate the benefits and harms of mesh using in hernia prevention.

NCT ID: NCT05939622 Completed - COVID-19 Clinical Trials

Efficacy of the Therapy With BRAINMAX® Using fMRI for the Treatment of Patients With Asthenia After COVID-19

Start date: May 18, 2022
Phase: Phase 4
Study type: Interventional

to assess executive network using resting-state fMRI and patterns of brain activation using task fMRI with a cognitive paradigm, against the background of taking the drug in comparison with placebo in patients with post-COVID asthenic syndrome.

NCT ID: NCT05939128 Recruiting - Breast Cancer Clinical Trials

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA

ERA
Start date: June 30, 2023
Phase:
Study type: Observational

(Neo)adjuvant treatment approaches and outcomes

NCT ID: NCT05935787 Recruiting - Stroke Clinical Trials

Cytoflavin in the Complex Rehabilitation of Stroke Patients

Start date: March 23, 2023
Phase: Phase 3
Study type: Interventional

It is known that the acute period of stroke occurs is accompanied by oxidative stress, when intense generation of reactive oxygen species (ROS) have a toxic effect, which causes oxidative degradation of proteins, lipids, nucleic acids. Antioxidants may have a positive effect on the processes of reparation, remodeling and neuroplasticity, thus improving the effectiveness of post-stroke rehabilitation. The adjunctive use of drug therapy that improves neuroplasticity may promote accelerated motor learning, which underlies the effects of exercise therapy and physical therapy, speech therapy, and sessions with a psychologist or occupational therapist. CYTOFLAVIN® is a combination of succinic acid, riboflavin, nicotinamide and inosine (riboxin) which has antihypoxic and antioxidant effects. The study hypothetizes that this neurometabolic drug will facilitate learning in stroke survivors and help to acquire new cognitive or motor skills necessary for daily living. The study will be conducted in two parallel groups of stroke survivors: the experimental group will be treated with Cytoflavin along with ohysical rehabilitation, the control group will receive standard rehabilitation course.

NCT ID: NCT05934799 Completed - Bioequivalence Clinical Trials

Bioequivalence Study of Two Formulations of Clopidogrel Film-coated Tablets 75 mg in Healthy Male Subjects Under Fasting Conditions

Start date: June 16, 2023
Phase: Phase 1
Study type: Interventional

This is an open-labeled, randomized, four period, single-center, crossover, full replicative, comparative study, where each participant will be randomly assigned to the reference (Plavix®, 75 mg film-coated tablets) or the test (Clopidogrel, 75 mg film-coated tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent.